Mometasona Korhispana (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, forming a complex that enters the nucleus and alters gene expression. This suppresses the production of inflammatory cytokines, chemokines and other mediators, leading to decreased inflammation, reduced immune cell infiltration, and alleviation of skin symptoms.

The specific amount, frequency and duration of application are determined by the prescribing clinician based on the severity of the skin condition, the area to be treated and patient age. Patients should follow the healthcare provider’s instructions and not exceed the prescribed regimen.

Safety data for topical mometasone furoate in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the prescribing clinician in consultation with the patient.

To request Mometasona Korhispana, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mometasone furoate is classified as a high‑potency topical corticosteroid, offering stronger anti‑inflammatory effects than low‑ to medium‑potency agents such as hydrocortisone or betamethasone valerate. It is often chosen for moderate to severe dermatoses where rapid symptom control is needed, while still being suitable for short‑term use on limited skin areas.

Store Mometasona Korhispana at temperatures below 25 °C in its original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain stability and potency throughout its shelf life.

The medication is applied topically to the affected skin area in a thin layer, usually once or twice daily as directed by a healthcare professional. Hands should be washed before and after application, and the treated area should be gently massaged until the product is fully absorbed.

Serious risks include skin atrophy, telangiectasia, secondary infections, and systemic corticosteroid effects such as adrenal suppression, especially with extensive or prolonged use. Patients should report any unusual thinning of the skin, persistent redness, or signs of infection to their clinician promptly.

Mometasona Korhispana should be avoided in individuals with known hypersensitivity to mometasone furoate or any excipients in the formulation, in patients with untreated skin infections at the application site, and in those where systemic corticosteroid exposure is contraindicated unless specifically advised by a physician.